COYA8:00 AMCoya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summitcoyatherapeutics.com
COYA7:35 AMCoya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updatecoyatherapeutics.com
COYA7:30 AMCoya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)coyatherapeutics.com
COYA8:00 AMCoya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALScoyatherapeutics.com
COYA8:00 AMCoya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Directorcoyatherapeutics.com
COYA8:00 AMCoya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapycoyatherapeutics.com
COYA8:00 AMCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Resultscoyatherapeutics.com